Results 61 to 70 of about 2,751,693 (208)

Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia

open access: yesCaucasian Medical Journal
Chronic myeloid leukemia (CML) is a myeloproliferative bone marrow neoplasm that occurs because of a fusion gene called BCR-ABL1. Imatinib -the inhibitor of this fusion geneis the target therapy in CML.
Aytan Shirinova
doaj   +1 more source

Gene expression signatures associated with the resistance to imatinib [PDF]

open access: yesLeukemia, 2006
Imatinib (imatinib mesylate, STI-571, Gleevec) is a selective BCR-ABL tyrosine kinase inhibitor that has been used as a highly effective chemoagent for treating chronic myelogenous leukemia. However, the initial response to imatinib is often followed by the recurrence of a resistant form of the disease, which is major obstacle to many therapeutic ...
Y-J, Chung   +11 more
openaire   +2 more sources

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva   +23 more
wiley   +1 more source

New Bcr-Abl-independent mechanisms of resistance to imatinib treatment in chronic myelogenous leukaemia patients [PDF]

open access: yes, 2008
Although rare in chronic phase myeloid leukemia (CML), primary or acquired resistance to the treatment with tyrosine kinase inhibitors (TKI) may be observed in the advanced phases of disease.
Esposito, Nicola
core   +1 more source

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation

open access: yesHaematologica, 2008
Treatment with imatinib is very effective in Bcr-Abl positive leukemia. However, development of resistance to this drug is a common phenomenon in late stage disease.
Rama Krishna Kancha   +5 more
doaj   +1 more source

Inhibin βB Mediates Oligotrophic Adaptation via Regulating Muscle Satellite Cell Proliferation and Differentiation in Schizopygopsis younghusbandi

open access: yesIntegrative Zoology, EarlyView.
① Nutrient deficiency upregulates inhibin βB, activating SMAD signaling to promote p21. Increased p21 inhibits mcm2/mcm4/mcm5 and cyclin E2, inducing G1‐phase arrest, slowing growth, and reducing energy consumption. ② Inhibin βB also upregulates pdgf‐c, which induces α‐SMA, leading to muscle satellite cell fibrosis.
Weiqiang Li   +16 more
wiley   +1 more source

RNA profiling and immunohistochemistry analyses of circRNAs in imatinib-resistant gastrointestinal stromal tumors

open access: yesJournal of Translational Medicine
Background Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal sarcomas of the upper digestive tract. Imatinib is the first-line therapy for patients with metastatic or unresectable GISTs.
Hanxing Tong   +8 more
doaj   +1 more source

Genomic analysis identifies an incipient signature to forecast imatinib resistance before start of treatment in patients with chronic myeloid leukemia

open access: yesAdvances in Biomarker Sciences and Technology
The unprecedented success of tyrosine kinase inhibitor (TKI), imatinib, to induce remission in 86 % of chronic phase (CP) patients of chronic myeloid leukemia (CML) is undermined by drug resistance. Few patients have primary resistance and do not respond
Rahul Mojidra   +6 more
doaj   +1 more source

Transporter pumps and imatinib: A cause of pharmacokinetic resistance? [PDF]

open access: yesCancer Biology & Therapy, 2008
Commentary to:Lack of ABC transporter autoinduction in mice following long-term exposure to imatinibErin R.
Klumpen, Heinz-Joseph   +2 more
openaire   +2 more sources

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

open access: yesAllergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy